New 'living pharmacy' biotech company launches out of Rice venture studio

fighting cancer

The company's HAMMR device is designed to produce therapeutic proteins inside the human body around the clock. Photo courtesy Rice University

Rice University’s biotech venture studio RBL LLC has launched a new “living pharmacy” company, Duracyte, designed to make cancer treatment easier on patients.

Backed by an up to $45 million Advanced Research Projects Agency for Health (ARPA-H) award, Duracyte aims to commercialize implantable biohybrid pharmacy devices that are designed to produce therapeutic proteins inside the human body around the clock, replacing the need for regular injections and infusions for some cancer patients.

The company’s main platform is its Hybrid Advanced Molecular Manufacturing Regulator (HAMMR), a rechargeable, implantable device that can sense biological signals, monitor tumor environments and adjust therapeutic output in real time. HAMMR has wireless communication capabilities, which allow patients and clinicians to remotely monitor results through an app every five minutes and make changes to treatment plans without a hosptial visit. Additionally, the device can generate its own oxygen supply, which is key for the therapeutic cells’ survival.

“Biologic medicines such as monoclonal antibodies, cytokines and metabolic regulators already account for a significant share of modern therapeutics, but the way we deliver them today often requires frequent injections or infusions that can be demanding for patients and lead to inconsistent drug levels,” Daniel Anderson, MIT professor and co-founder of Duracyte, said in a news release. “Our vision is to enable a continuous, stable therapy by producing these medicines directly inside the body, which could improve treatment consistency, reduce side effects and ultimately transform how biologic therapies are delivered across many diseases.”

Duracyte’s first clinical trial is slated to begin by the end of 2026 and will focus on recurrent ovarian cancer. The Phase I study will build upon existing work on encapsulated cytokine pharmacy technology, and the company hopes that within a few years this treatment can reach clinical application.

The development of Duracyte is supported by ARPA-H's Targeted Hybrid Oncotherapeutic Regulation (THOR) project, which supports a multidisciplinary research consortium co-led by Omid Veiseh, a professor of bioengineering at Rice. The consortium also includes others at Rice, The University of Texas MD Anderson Cancer Center, Stanford University, Carnegie Mellon University, Northwestern University and the University of Houston, plus industry collaborators like Chicago-based CellTrans.

“What we are building is the culmination of years of progress in cell engineering, biomaterials and implantable device technology,” Veiseh added in the release. “By combining these advances with real-time sensing and adaptive drug delivery, we are working with the support of RBL to create a true ‘living pharmacy’ that can deliver continuous, precisely controlled biologic therapies and fundamentally change how these treatments reach patients.”

RBL launched in 2024 and is based out of Houston’s Texas Medical Center Helix Park. Duracyte is the third company launched by RBL, including Sentinel BioTherapeutics, a clinical-stage immunotherapy company developing localized cytokine therapies for solid tumors, and SteerBio, a regenerative medicine company targeting lymphedema.

“Duracyte exemplifies the kind of breakthrough that Houston’s ecosystem is built to produce,” Paul Wotton, managing partner of RBL LLC and co-founder of Duracyte, added in the release. “With world-class clinical infrastructure, exceptional engineering talent and initiatives like the Texas Biotech Task Force driving alignment across industry, investment and talent, this region is uniquely positioned to move the most ambitious ideas in medicine from concept to patient, faster than anywhere else.”

From Your Site Articles

RBL LLC has landed an investment from Houston-based Modi Ventures and named its founder, Sahir Ali (far left), to its board. Photo courtesy Rice University Biotech Launch Pad via LinkedIn

Rice biotech studio secures investment from Modi Ventures, adds founder to board

fresh funding

RBL LLC, which supports commercialization for ventures formed at the Rice University Biotech Launch Pad, has secured an investment from Houston-based Modi Ventures.

Additionally, RBL announced that it has named Sahir Ali, founder and general partner of Modi Ventures, to its board of directors.

Modi Ventures invests in biotech companies that are working to advance diagnostics, engineered therapeutics and AI-driven drug discovery. The firm has $134 million under management after closing an oversubscribed round this summer.

RBL launched in 2024 and is based out of Houston’s Texas Medical Center Helix Park. William McKeon, president and CEO of the TMC, previously called the launch of RBL a “critical step forward” for Houston’s life sciences ecosystem.

“RBL is dedicated to building companies focused on pioneering and intelligent bioelectronic therapeutics,” Ali said in a LinkedIn post. “This partnership strengthens the Houston biotech ecosystem and accelerates the transition of groundbreaking lab discoveries into impactful therapies.”

Ali will join board members like managing partner Paul Wotton, Rice bioengineering professor Omid Veiseh, scientist and partner at KdT Ventures Rima Chakrabarti, Rice alum John Jaggers, CEO of Arbor Biotechnologies Devyn Smith, and veteran executive in the life sciences sector James Watson.

Ali has led transformative work and built companies across AI, cloud computing and precision medicine. Ali also serves on the board of directors of the Drug Information Association, which helps to collaborate in drug, device and diagnostics developments.

“This investment by Modi Ventures will be instrumental to RBL’s growth as it reinforces confidence in our venture creation model and accelerates our ability to develop successful biotech startups,” Wotton said in the announcement. "Sahir’s addition to the board will also amplify this collaboration with Modi. His strategic counsel and deep understanding of field-defining technologies will be invaluable as we continue to grow and deliver on our mission.”

Sentinel BioTherapeutics is developing cytokine interleukin-2 (IL-2) capsules to fight many solid tumors. Photo via Getty Images.

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

This week's roundup of Houston innovators includes Chris George of Octopus EV, James Allison of MD Anderson, and Paul Wotton of RBL LLC. Photos courtesy

3 Houston innovators to know this week

who's who

Editor's note: Every week, I introduce you to a handful of Houston innovators to know recently making headlines with news of innovative technology, investment activity, and more. This week's batch includes a biotech leader, a Nobel laureate, and EV innovator.

Chris George, United States co-lead at Octopus Electric Vehicles

Chris George, United States co-lead at Octopus Electric Vehicles, joins the Houston Innovators Podcast. Photo courtesy of Octopus

Switching from a gas-powered car to an electric one can be a big change, but a Houston-based company has made things a lot easier for its customers.

Octopus Electric Vehicles US, a spinout of United Kingdom-based retail energy provider Octopus Energy, matches its users with their perfect EV lease and sets them up with smart electricity technology for at-home charging.

"We do a couple of really unique things that are not only first of its kind but really innovative," Octopus EV's US Co-Lead Chris George says on the Houston Innovators Podcast, pointing out specifically Octopus Energy's Intelligent Octopus, a smart feature for customers that automates energy usage to lower cost.

"We launched an Intelligent Octopus for EVs service. Instead of operating in a very narrow window — overnight — it operates dynamically," he continues. Read more.

James P. Allison, director of the James P. Allison Institute

MD Anderson's lab led by Nobel laureate James Allison has secured a $5 million donation. Photo courtesy of MD Anderson Cancer Center

The James P. Allison Institute at The University of Texas MD Anderson Cancer Center scored a $5 million gift at its second annual symposium.

On behalf of Mayor John Whitmire, Oct. 10, 2024 was named “James P. Allison Institute Day,” and it was also the day that the TMC3 Collaborative Building in the Texas Medical Center’s Helix Park greeted 900 attendees for the scientific symposium, entitled “Immunotherapy in Space and Time: The Tumor Microenvironment.”

“Spatial biology is a rapidly expanding field that offers tremendous new insights into immunobiology that were not possible just a few short years ago. Understanding how immune cells interact with their neighbors and with tumor cells in space and time will enable us to bring forward new strategies to improve immunotherapy outcomes,” says James P. Allison. “We are proud to host this annual symposium to advance the field, and we are extremely grateful for the support of the Wintermann Foundation to make new breakthroughs possible.” Read more.

Paul Wotton, managing partner of RBL LLC

Established to rapidly build companies based on Rice University's portfolio of over 100 patents, RBL LLC is Rice University's new biotech venture creation studio based in Texas Medical Center Helix Park. RBL comes on the heels of establishing the Rice Biotech Launch Pad, a biotech innovation accelerator that opened last year.

Paul Wotton, executive director of the Rice Biotech Launch Pad, co-founded RBL with his colleagues Omid Veiseh, Rice professor of bioengineering and faculty director of the Rice Biotech Launch Pad; Jacob Robinson, Rice professor of electrical and computer engineering; and Dr. Rima Chakrabarti, a physician scientist and venture capital investor with KdT Ventures.

“This is a pivotal moment for Houston and beyond,” Wotton, who serves as RBL’s managing partner, says in a news release from Rice. “Houston has rapidly emerged as a global life sciences powerhouse, blending cutting-edge research with early clinical applications at Rice and the city’s world-renowned hospital systems." Continue reading.

Rice University opens biotech venture studio in TMC

rapidly scaling

In its mission to amplify and advance biotech innovation, Rice University has announced its latest initiative — a new lab focused on bringing life-saving medical technologies to commercialization.

Established to rapidly build companies based on Rice University's portfolio of over 100 patents, RBL LLC is a new biotech venture creation studio based in Texas Medical Center Helix Park. RBL comes on the heels of establishing the Rice Biotech Launch Pad, a biotech innovation accelerator that opened last year.

"Investors from across the nation are recognizing Houston’s potential, and with RBL, we’re building on that momentum," he continues. "We’ll not only amplify the work of the Rice Biotech Launch Pad but expand our reach across Texas, creating opportunities for biotech ventures statewide and driving growth for the biotech industry as a whole.”

Strategically located in TMC, RBL will collaborate with medical leaders, investors, corporations, and other players both in the same building and on the greater TMC campus.

“Leveraging Rice University’s Biotech Launch Pad breakthroughs and pairing it with the world-class translational infrastructure of TMC Helix Park well positions RBL to drive unprecedented advances in patient care,” William McKeon, president and CEO of the TMC, says in the release. “This partnership between academia, industry and health care is exactly what’s needed to transform medical discoveries into real-world solutions that improve lives globally.”

RBL is Rice's latest effort to bridge the gap between academia and biotech innovation, an effort led by Paul Cherukuri, Rice’s chief innovation officer, who reportedly spearheaded development of the new initiative.

“RBL is a game-changer for Rice, Houston and the global biotech community,” Cherukuri adds. “This venture not only accelerates the commercialization of our innovations but also sets a blueprint for other universities looking to maximize the real-world impact of their discoveries. By combining scientific expertise with entrepreneurial support from Day Zero together with strategic clinical partnerships in the TMC, we’re creating a model for driving large-scale biotech innovation that universities everywhere should aspire to replicate.”

Since the Rice Biotech Launch Pad was established, Motif Neurotech closed its series A round with an oversubscribed $18.75 million, the hub secured a $34.9 million grant, and a “living pharmacy” founded at the Launch Pad received industry validation.

“RBL provides a powerful platform to translate high-impact scientific discoveries into therapies that will dramatically improve patient outcomes,” Veiseh says. “Our goal is to rapidly bring Rice’s pioneering research into the clinic, delivering life-saving solutions to patients around the world.”

The first of Rice University's new moonshot initiatives, the Rice Biotech Launch Pad was announced on the 61st anniversary of President John F. Kennedy's address at Rice Stadium. Photo by Gustavo Raskosky/Rice University

New biotech lab, accelerator emerges in Houston to speed up commercialization of life-saving cures

ready to launch

A new initiative from Rice University is launching with an ambitious goal — to take biotech innovations from concept to clinical trials in five years or less.

The Rice Biotech Launch Pad is a newly announced initiative that will expedite Rice University's health and medical technology innovations. The accelerator, which will occupy 15,000 square feet of space on campus, will be funded through federal grants and donations.

“The Rice Biotech Launch Pad will ensure that our faculty and students have the skills, partnerships, tools and support to create technologies that can transform our city and the world,” Rice President Reginald DesRoches says in a press release. “More importantly, the accelerator will provide a pathway for these creations and discoveries to be turned into medical cures that significantly impact people’s lives. Rice researchers have been doing this for years. This development will allow them to do even more and at a quicker, more efficient pace.”

Leading the program are two seasoned experts: associate professor of bioengineering at Rice, Omid Veiseh, and biotech entrepreneur Paul Wotton, who co-founded Avenge Bio and other startups with technology discovered in Veiseh’s lab. Veiseh will serve as faculty director, and Wotton will lead as executive director. Veiseh says the team behind the new lab will assist faculty in their mission to garner funding — via grants from organizations such as ARPA-H, DARPA and the NIH — as well as creating pathways for licensing revenue for the university.

“We have the infrastructure, financial backing and talent in Houston to do more in creating new medicines to cure disease," Veiseh says in the release. "This is a thriving environment that warrants more attention and dedication to bring forward Houston’s medical discoveries. I am proud to help make this happen.”

The accelerator’s founding advisory council members from Rice are:

Paul Cherukuri, Rice’s vice president for innovation.
Jacob Robinson, professor of electrical and computer engineering and of bioengineering and founder and CEO of Motif Neurotech.
Ashok Veeraraghavan, professor of electrical and computer engineering and computer science and co-founder of Synopic.
Yael Hochberg, head of the Rice Entrepreneurship Initiative and the Ralph S. O'Connor Professor of Finance and Entrepreneurship at the Jesse H. Jones Graduate School of Business.

“The Biotech Launch Pad is the first in a series of Rice Moonshots that are hyper-focused on building a ‘speed and scale’ innovation ecosystem across Houston," Cherukuri says. "We at Rice are committed towards driving the Biotech Launch Pad in collaboration with our partners within the Texas Medical Center and the new Helix Park campus.”

Ad Placement 300x100

Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

KBR announces name, brand for government services spinoff

new identity

Houston-based KBR Inc.'s new Mission Technology Solutions unit officially has a name.

The previously announced government services spinoff, which until now has been nicknamed SpinCo, will now be known as Trinzic. The company said in a news release that the name was inspired by the word intrinsic, "reflecting essential, built-in capabilities and deep expertise operating in some of the world’s most complex and mission-critical environments."

New York-based firm Siegel + Gale developed the company's new brand. In addition to the new name, the company shares that its new logo will feature a stylized letter N, with brand colors in orange and gray.

“Trinzic represents who KBR Mission Tech has always been at our core: an essential partner bringing innovation and trusted execution to the missions that matter most,” Stuart Bradie, KBR President and CEO, said in the release. “The new Trinzic brand represents both our strong heritage and the tremendous opportunity ahead. Our teams aim to deliver solutions that address some of the world’s most critical national priorities every day, and this new identity captures the purpose-driven culture and mission focus that we expect to continue to define the company moving forward.”

KBR expects the spin-off to be completed in January 2027. At that time, Trinzic will operate as an independent, publicly traded company that will focus on technology and engineering services for the space and national security sectors.

KBR will remain a separate publicly traded company that will focus on sustainable technology and services to support the energy transition. KBR first announced the spinoff plans in October 2025.

Last month, KBR announced two C-suite hires for Trinzic, or what was then known as SpinCo.

Michael LaRouche will serve as Trinzic's inaugural president and CEO. LaRouche is currently CEO of Serco North America, a Virginia-based government services contractor. Nicholas Veasey, current CFO of Virginia-based MAG Aerospace, was named Trinzic's CFO. Bradie will remain chairman, president and CEO of KBR.

Rice lands $19M NSF grant to build AI-driven quantum materials lab

Quantum Boost

Rice University has received a $19.9 million award from the National Science Foundation to increase the production of quantum and electronic materials by using a combination of artificial intelligence, cloud-based labs and robotics.

The four-year project will create a remote and automated research platform that aims to accelerate discovery and the testing process, according to Rice. The aptly titled project, "Revolutionizing AI-Driven Autonomous Experimentation for Next-Generation Semiconductor Synthesis” (READINESS), will be led by Rice materials scientist Jun Lou, who serves as principal investigator. SUNY Polytechnic Institute and the University of Texas at Austin will collaborate with Rice on the project.

At first, READINESS will focus on two-dimensional materials, oxide semiconductors and diamond thin films that can support emerging technologies, like quantum devices.

READINESS is one of 20 projects selected for the NSF's Programmable Cloud Laboratories Test Bed initiative, which aims to provide more U.S. researchers with access to automated scientific tools.

Additionally, the project aligns with the Department of Energy’s Genesis Mission, which recently selected four projects from Houston universities and companies, including two from Rice. The national initiative aims to unite government, industry, academia and philanthropy to lead to breakthroughs in energy, scientific discovery and national security.

READINESS will offer more advanced lab systems remotely via a cloud interface to assist startups, other research groups, and companies that don’t have the resources, staffing or equipment to produce quantum materials and advanced electronics. READINESS will also allow researchers to simulate experiments via virtual experiments or digital twins before they conduct the physical experiment.

Rice says this will be particularly useful in quantum materials research, which is often met with barriers— like the adjustments of chemical composition, gas flow, pressure, and temperature—that can change the properties of a material.

“This project will give researchers access to capabilities that have traditionally been available only in a handful of laboratories,” David Sholl, executive vice president for research at Rice, said in a news release. “By lowering those barriers, READINESS can accelerate discovery and expand who can participate in cutting-edge materials research.”

Additionally, the project’s AI aspect will offer recommendations for new tests, recognize safety limits and analyze results to assist researchers.

“Responsible AI should complement researchers’ capabilities rather than replace their judgment,” Luay Nakhleh, Dean of Rice’s George R. Brown School of Engineering and Computing, added in the release. “READINESS embodies this principle by combining automated systems with transparency, safeguards and human oversight at critical decision points.”

READINESS’ lab will be based out of Rice’s Ralph S. O’Connor Building for Engineering and Science. Partner sites will also contribute equipment, expertise and workforce development programs, according to Rice.

Ultimately, READINESS aims to elevate the speed, reliability and reproducibility of experiments, and to promote access to automated scientific tools for U.S. researchers.

“Our goal is to create a laboratory that researchers from across the country can use to produce advanced electronic and quantum materials on demand,” Lou added in the release. “By integrating robotics, AI and digital twins, we aim to learn from every experiment and shorten the pathway from scientific discovery to practical technology.”

10+ can't-miss Houston business and innovation events for August

where to be

School is back in session this month, and a busy slate of Houston business and innovation events follows. This month brings demo days, loads of networking opportunities and a major health symposium. Here’s what not to miss and how to register. Please note: this article may be updated to add more events.

Aug. 4 — CEOs: Build With AI, Exit With a Premium

Join Blue People for this engaging presentation by David Lopez, founder of Summa, at the latest installment of Tech + Tequila Talk. Lopez will discuss AI moves that can multiply a company's value.

This event is Tuesday, Aug. 4, from 5-7 p.m. at the Ion. Register here.

Aug. 4 — SEIP Demo Day

The Rice Center for Engineering Leadership will showcase the groundbreaking projects developed by its Summer Engineering Innovation Program at the 2026 Demo Day. Attendees can meet the SEIP participants and partners and hear the teams' final presentations.

This event is Tuesday, Aug. 4, from 6-8 p.m. at the Ion. Register here.

Aug. 5 — Summer Venture Studio Preview Day

The Liu Idea Lab for Innovation and Entrepreneurship (Lilie) will present its inaugural Summer Venture Studio Preview Day this month. Hear from the student founders selected for Lilie's summer cohort, which features teams ranging from the healthcare and artificial intelligence to advanced manufacturing sectors.

This event is Wednesday, Aug. 5, from 4-6 p.m. at the Ion. Register here.

Aug. 11 — Mercury Fund Day at the Ion: How Legacy Software Giants Are Going AI-First

Don’t miss the latest installment of Mercury Fund Day at the Ion, previously known as Software Day. The recurring monthly event features office hours (by application), a keynote and networking opportunities. This month's topic will feature a working conversation with Senior Director of Growth at Twilio Mustafa Ali, Senior Director of Consumer Product at WhatsApp Zafir Khan, and Founder and CEO of utilITise Salim Gheewalla.

This event is Tuesday, Aug. 11, from 3:30-7 p.m. at the Ion. Register here.

Aug. 13 — Pints and Prototypes

TMC Innovation Lab will host its Pints & Prototypes networking event this month. Minneapolis-based Medtronic will support this month's event and has invited guest speakers to share their journey in the medtech scene.

This event is Thursday, Aug. 13, from 4-5:30 p.m. at TMC Innovation Factory. Find more information here.

Aug. 14 — Houston Methodist Cancer Symposium

The 14th Annual Houston Methodist Cancer Symposium will bring together Houston Methodist scientists and physicians from a broad spectrum of fields to discuss everything from innovative translational science to clinical updates. The symposium aims to provide education focused on improving patient care, research collaboration and leading medicine.

This event is Friday, Aug. 14, from 7:30 a.m.-4:45 p.m. at Houston Methodist Research Institute. Find more information and register here.

Aug. 14 — Hands-On Workshop: Build Your Own Reusable AI System

Impact Hub Houston and Social Media Breakfast of Houston will host this hands-on workshop on using Smart Card to create a repeatable process users can hand off to AI. Attendees should bring a laptop, an AI tool, and a task that AI could help with. The workshop will focus on working with ChatGPT, Claude or Gemini.

This event is Friday, Aug. 14, from 8:30-10:30 a.m. at the Ion. Register here.

Aug. 17-21 — Foundations of Cancer Therapeutics Crash Course

The Gulf Coast Consortia will host a virtual course focused on the commercialization aspects of moving cancer therapeutics toward the market. Presenters represent The University of Texas Medical Branch Galveston, the Greater Houston Partnership, TMC Innovation, the University of Houston, Texas Southern University and other major institutions.

This event begins Monday, Aug. 17, at 10 a.m. Register here.

Aug. 20 — Pickle Lab’s Two-Year Anniversary Celebration

Enjoy an evening of open-play pickleball, beats by a live DJ, giveaways and more at the second anniversary celebration of Pickle Lab in the Ion District. Enjoy a free beverage from Second Draught and food for purchase from the Crunchy’s for the Munchies food truck.

This event takes place Thursday, Aug. 20, from 6-9 p.m. at Pickle Lab at the Ion. Register here.

Aug. 20 — SBA Lender Matchmaking Event

Business owners can meet with multiple lenders in scheduled, one-on-one 15-minute sessions during this speed-dating style SBA event. SBA Houston District Office representatives will also be onsite to provide free business advising.

This event takes place Thursday, Aug. 20, from 8:30 a.m.–noon at SBDC Sam Houston State University – The Woodlands Center. Register here.

Aug. 27 — BiteLabs Digital Health and Innovation Summit

TMC Innovation and BiteLabs will host the Digital Health and Innovation Summit, which aims to connect clinicians, founders and investors. The event will include an AI in biotech panel, a healthcare AI ethics panel, a hiring in digital health panel, and pitches from BiteLabs USA HealthTech, AI, and Innovation Fellowship.

This event takes place Thursday, Aug. 27, from 10 a.m.–5 p.m. at TMC Innovation Factory. Register here.

View All Listings

INNOVATIONMAP EMAILS ARE AWESOME